Human LTA4H is a bifunctional enzyme with epoxide hydrolase and aminopeptidase activities employing the same active site containing single divalent metal (Zn 2+ ) ion [1] . The inhibition of this enzyme reported to effectively combat the inflammation process, which is a complex mechanism regulated by a variety of cellular and soluble factors [2] . These factors include eicosanoids, a class of structurally related paracrine hormones derived from arachidonic acid (A A) which includes prostaglandins, leukotrienes (LT) and lipoxins [3] . The LT are a family of lipid mediators associated with acute and chronic inflammatory disease such as asthma, rhinitis and atherosclerosis [4] . The biosynthesis of LT occurs in response to a set of immune and inflammatory signals that mobilize intracellular calcium. This promotes the phosphorylation and membrane translocation of cPLA2 and 5-lipoxygenase. The PLA2 releases AA by acting upon membrane-bound phospholipids followed by the conversion of released AA to highly unstable allylic epoxide, LTA4 upon the action of 5-lipoxygenase activating protein [1] . This highly unstable intermediate is subsequently metabolized by the hydrolase activity of hLTA4H and glutathione transferase activity of LTC4S to form LTB4 and LTC4, respectively. It is generally assumed, although it is not experimentally verified, that the aminopeptidase activity of hLTA4H is involved in the processing of peptides related to inflammation and host defense [5, 6] . This peptidase activity of LTA4H was found to be activated by several monovalent anions such as thiocyanate, chloride and bromide ions, as well as albumin [3] . The LTB4 is a potent pro-inflammatory agent involved in various inflammatory responses and two G-protein-coupled receptors, namely, BLT1 and BLT2 mediate its inflammatory property [7, 8] . This property of LTB4 is implicated in many inflammatory diseases such as asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, arthritis, psoriasis, and atherosclerosis [9] [10] [11] [12] [13] [14] [15] [16] . Among the widely observed pro-inflammatory effects, only recently the benefits of LTB3 and LTB4 in host-defense were recognized. A variety of stable synthetic LTB3 and LTB4 analogues have been produced to overcome the limitations because of their unstable nature towards metabolism [17] . An increased risk of myocardial infarction and stroke is also recently reported to be related with increased production of LTB4 [18] . Variety of chemical compounds of diverse chemotypes was developed as inhibitors of hLTA4H to be used in the treatment of anti-inflammatory diseases [18] [19] [20] [21] . There is a need for novel and potent LTA4H inhibitors to treat various inflammatory diseases despite of a few marketed therapeutic products, such as zileuton [22] , zafirlukast [23] and montelukast [24] , and drug candidates that are Development of predictive quantitative structure-activity relationship model and its application in the discovery of human leukotriene A4 hydrolase inhibitors Background: Human LTA4H catalyzes the conversion of LTA4 to LTB4 and plays a key role in innate immune responses. Inhibition of this enzyme can be a valid method in the treatment of inflammatory response exhibited through LTB4. Results & discussion: The quantitative structure-activity relationship (QSAR) models were developed using genetic function approximation and validated. A training set of 26 diverse compounds and their molecular descriptors were used to develop highly correlating QSAR models. A six-descriptor model explaining the biological activity of the training and test sets with correlation values of 0.846 and 0.502, respectively, was selected as the best model and used in a database screening of drug-like Maybridge database followed by molecular docking. Conclusion: Based on the predicted potent inhibitory activities, expected binding mode and molecular interactions at the active site of hLTA4H final leads were selected as to be utilized in designing future hLTA4H inhibitors. in different phases of clinical trials. Numbers of crystal structures are available for hLTA4H in free and complex forms bound with chemically diverse set of inhibitors at the active site [18, [25] [26] [27] [28] [29] . High structural similarity was observed between the catalytic domain of hLTA4H and bacterial metalloprotease thermolysin including conserved zinc-binding active site motif in the 17-Å long and L-shaped active site cavity containing H295, H299 and a carboxyl atom of E318 as main coordinative elements to bind the metal ion (FiguRe 1) [25, 29] .
Several statistical methods such as multiple linear regressions, partial least squares, neural networks, molecular field analyses, and principal component analyses were frequently employed in developing quantitative structure-activity relationship (QSAR) models [30] [31] [32] [33] [34] . The genetic function approximation (GFA) is a novel optimization method based on the evolution process of beings [24] . Because of its effectiveness, GFA has been applied to the various types of optimization problems in many scientific areas. Recently, our group developed pharmacophore model for the discovery of hLTA4H inhibitors. This study has used Bayesian models in the identification of the fragments that favored the inhibitory activity [35] . Another study aimed at identifying dual inhibitors that can effectively inhibit hLTA4H and hLTC4S employing common feature pharmacophore modeling and pharmacophore-based filtering methodologies was performed [36] . In this study, GFA technique was employed to develop a highly predictive QSAR model for hLTA4H enzyme inhibitors. We have also employed the stepwise multiple linear regressions method with the same samples used in this study but their results were statistically insignificant compared with the GFA results. Thus, their results were not discussed in this study. Two different sets of experimentally tested hLTA4H inhibitors were generated from the dataset retrieved from the literature were used in model development as well as in validating the developed models. The model that predicts the biological activities of the test set compounds with high correlation was selected and used in estimating the biological activities of chemical compounds in a database. Based on the molecular interactions and binding modes, the compounds from the database with estimated activity values of potent range were selected as potential leads to be utilized in future hLTA4H inhibitor design.
Methods & materials
Collection of data set The hLTA4H inhibitory activity of a chemical compound is determined using various biological assays, to date [19, 20, 37] . A set of chemical compounds developed to inhibit this enzyme and thereby possess the anti-inflammatory effect were collected from the literature. From the set of collected compounds, we have selected the compounds tested for the inhibitory activity using similar biological assay conditions and measured in IC 50 values. This data set included a total of 142 compounds of substantial chemical diversity and activity ranged from 0.5 nM to 9700 nM. The diverse nature of these compounds included the derivatives of: Kelatorphan [37] [38] [39] [40] [41] [42] [43] .
All of these finally selected compounds were sketched using Chemsketch Version 12 program and exported to Accelrys Discovery Studio 2.5 (DS) program (Accelrys Inc., CA, USA) to be converted in to 3D structures. These compounds were energy minimized using smart minimizer protocol available in DS, which minimizes a compound employing steepest descent algorithm with a root-meansquare gradient tolerance of 3, followed by conjugate gradient algorithm.
Calculation of descriptors
The complete set of minimized compounds was utilized in calculating various descriptors to derive a mathematical relationship to explain the biological activity of a chemical compound. A variety of 2D and 3D descriptors as available in DS was calculated for all the compounds in the data set. The 2D descriptors include ALogP, molecular property counts, and surface area and volume whereas the 3D descriptors included dipole, jurs and shadow indices. Along with these 2D and 3D descriptors calculated from DS, molecular docking parameters were also calculated by docking the complete dataset in to the active site of hLTA4H (PDB code: 3FH7) using genetic optimization for ligand docking (GOLD) 4.1 program [44] . The crystal structure was prepared for docking by removing the water molecules and other smallmolecule fragments, except the inhibitor and catalytically important divalent metal (Zn 2+ ) ion present in the structure. After adding hydrogen atoms, a binding site with the size of approximately 10 Å the bound inhibitor was created. This size of the binding site was chosen in order to include all the important active site residues known to be involved in inhibitor binding. The available early termination option was set to 5 from the default value of 3 to prompt the program to stop or skip the docking calculation for a particular compound if any of its five conformations were within the root-mean-square deviation value of 1.5 Å. The GOLD uses the genetic optimization algorithm to dock the chemical compounds by keeping the macromolecule rigid/partially flexible and flexibly docking the small molecules [45] . In this study, the protein molecule was kept rigid during the molecular docking calculations. The calculated parameters from this molecular docking study were also used as descriptors in QSAR model generations. The parameters such as fitness score, internal van der Waals (VDW), internal torsion, external VDW and external H bond calculated from molecular docking using GOLD were considered in QSAR model generations.
Selection of training set
The selection of a training set representing the diverse nature of the full data set in terms of chemical structure and activity is very important for any QSAR study as this set is the source of information based on which the models are built. In this study, a set of 26 compounds with considerable diversity was selected to be used in the generation of QSAR models (FiguRe 2 ). This training set included two compounds of aryl diamine and piperidine derivatives, respectively, seven compounds of pyrrolidine, one compound of imidazopyridine, five compounds of N-alkyl glycine amide, seven compounds of propanoic acid and two compounds of kelatorphan derivatives. These compounds with their inhibitory activities targeting hLTA4H enzyme were selected and the inhibitory activities measured in IC 50 values were changed to the minus logarithmic scale (pIC 50 nM) before using them as dependent variable in QSAR analyses. The 2D, 3D and docking descriptors of the training set compounds calculated using DS and GOLD programs were used in QSAR model generation. The terminologies and definitions of all the descriptors used in this study are given in the help topics of DS.
Development of different QSAR models
The GFA, a statistical technique, was employed in generating QSAR models with the chemical structures and descriptor values of the prepared training set of 26 compounds. Among the calculated descriptors, the descriptors not showing any contribution or showing constant calculated values for all the compounds were rejected from the study. The intercorrelation values were also taken into consideration before developing the models. The descriptors with high correlation values toward the dependent variable (pIC 50 ) were selected from the group of calculated descriptors. Three different QSAR models using GFA technique were developed with preferred descriptors. The GFA uses a genetic-based technique in terms of variable selection, which is a very difficult task in other statistical approaches. This is the combination of Holland's genetic algorithm and Friedman's multivariate adaptive regression splines [46, 47] . It is majorly used to reduce the large number of descriptors in to small set that possibly correlate the response [48] . Three operations, namely, selection, crossover and mutation are performed in successive iteration in GFA. The default values of 100 and 5000 for population size and Development of predictive quantitative structure-activity relationship model | ReseaRch aRticle www.future-science.com maximum generations, respectively, were used in this study. The goodness of each generation was evaluated by Friedman's lack-of-fit (LOF) score, which is calculated using the least-square error, number of basis function, smoothing parameters that control the number of terms, descriptors and observations in the training set. This method generates a series of significant models to a set of given structures and descriptors. These models are modified and tested repeatedly to produce an optimal model [46, 49] . Three QSAR models correlating the biological activity (dependent variable) with or without a docking descriptor and fingerprints were generated. Every GFA run has produced ten models explaining the response with a set of descriptors. As the training set is containing only 26 compounds, the number of descriptors between 4 (minimum) and 10 (maximum) was selected. The best among the ten models was chosen based on the statistical parameters such as regression coefficient (r 2 ), cross validated r 2 (cv_r 2 ), Friedman's LOF and significance of regression p-value.
Validation of models
The developed models were validated before using them in predicting the inhibitory activity values of newly designed chemical compounds or compounds in a commercially available chemical database. The 116 compounds in the primary data set not utilized in the development of QSAR models were selected to be in the test set. This test set also composed of compounds of diverse nature in terms of chemical structure and activity as observed in training set. The Calculate Molecular Properties protocol as available in DS was used to predict the IC 50 values of the test set compounds. All three developed QSAR models were employed in test set prediction and the best model was selected based on the predicted r 2 value.
Screening drug-like database & molecular docking Screening a chemical database for potential drug candidates to be utilized in designing novel and potent drugs, as such or upon optimization, for a particular therapeutic target has been a great interest from medicinal chemistry perspective. This process skips the designing of new synthetic route and purification steps that are laborious by providing the readily available compounds or for which the synthetic routes are known. Maybridge (Maybridge Chemical Co., Cornwall, UK), a commercial chemical database containing 59,652 compounds, has been used in this study. However, this database is found to have number of nondrug-like compounds. As it is meaningless to dock all the compounds of this database into the active site of protein target to calculate the docking descriptors and then reject them in the later stage for their nondruglike properties, the compounds with nondruglike properties were excluded from the database prior to molecular docking. In order to achieve this step, compounds in the Maybridge database were subjected to various rigorous drug-like filters such as Lipinski's rule of five [50] and, absorption, distribution, metabolism, excretion and toxicity (ADMET) properties [51] [52] [53] . The prepared ligands and ADMET descriptors protocols as available in the DS program were used in this step. This drug-like database generated from Maybridge chemical database was used in screening in order to identify the compounds scoring high predicted IC 50 values with favorable physicochemical properties. The compounds scoring better or similar predicted IC 50 values to the most active compounds in the data-set collected from the literature were selected. These compounds were further filtered based on their binding modes and molecular interactions with catalytic active site residues and reported as possible lead candidates to be utilized in potent inhibitor design.
Results & discussion
Characteristic of the binding site The hLTA4H enzyme is made up of three distinctive domains, namely, N-terminal (residues 1-207), catalytic domain (residues 208-450), and C-terminal (residues 461-610) [29, 54] . The catalytic binding pocket is located at the interface of these domains mostly towards the catalytic domain, hence, the name (FiguRe 1) . Whereas the N-terminal is completely composed of long-stranded b-sheets the other two domains are made of a-helices. The metal ion-binding site is formed by amino acid residues only from the catalytic domain such as H295, H299 and carboxylic oxygen of E318, which coordinate with the atom of substrate or inhibitor [29] . The binding pocket present at the interface is highly hydrophobic in nature and the cavity is approximately 6-7-Å wide and 15-Å deeper into the protein. This enzyme exhibits both epoxide hydrolase and aminopeptidase activities using an overlapping but distinct active sites. The amino acid residues E271, R563 and the Zn 2+ are important for both mechanisms [54] . This Development of predictive quantitative structure-activity relationship model | ReseaRch aRticle www.future-science.com enzyme is inactivated and covalently modified by its substrate LTA4 during its catalysis where Y378 has been identified as the major residue that binds during this inactivation [55, 56] .
Molecular docking & selection of best poses
The complete data set of 142 compounds were docked in to the active site of hLTA4H with the docking parameters discussed previously. The conformation of a particular compound scoring a high GOLD fitness score was considered as the best conformation. The docking descriptors of this particular conformation were noted and used in QSAR model development. The selection of best pose was also influenced by the binding mode and molecular interactions with very important active site residues and the metal (Zn 2+ ) ion. The crystal structure of hLTA4H-inhibitor complex, 3FH7, was used in molecular docking study as it is bound with one of the most active LTA4H inhibitors, to date. The binding conformation of this inhibitor was considered as a reference to select the conformations of the docked training set compounds with similar binding mode and molecular interactions. This inhibitor forms a hydrogen bond network with H295, H299 and Y383 along with a coordinate interaction with the metal ion through its carboxyl group. Thus, the conformations of docked compounds of the data set were selected when it binds and interacts similarly. Most of the compounds from the most active class have scored high GOLD fitness scores compared with that of least active class. This trend represented the ability of the GOLD program in predicting the biologically meaningful binding modes of inhibitors at the active site of LTA4H enzyme. The validation result from our previous study has also proved the reliability of GOLD program in terms of LTA4H enzyme [2] .
Development of QSAR models
Three models with different set of descriptors were developed out of the training set compounds with their dependent and independent descriptors. All the models generated in this study are hybrid models of 2D and 3D descriptors. (table 2) . In contrast to the previous two models, this model was developed with no GOLD docking descriptor but by the mixture of 2D and 3D descriptors (box 1). The q 2 value was low compared with the previous models showing that it can predict 68.10% of variance and the difference between r 2 and q 2 was high compared with the other models. All the residual values were within one order of magnitude indicating the quality of prediction (table 3) . The only advantage of this model over other models is the number of descriptors used to develop the model. This model is built using only six descriptors whereas others were built with 9 and 8 descriptors. Thus, the probability is high for a particular compound to possess six scoring descriptors than eight or nine scoring descriptors. For this reason, an external test set was used to validate the predictive ability of the models.
Validation of generated models Validating the QSAR models to investigate their ability in predicting the activity of the compounds not used in developing the model is of great importance. For this purpose, a set of experimentally tested compounds using the same biological assay conditions as training set compounds was used as an external test set. The molecular docking and other descriptors that were used in generating the model equations were calculated for the test set compounds with the same parameters. A set of 116 diverse compounds with their pIC 50 values was used in this validation. All three developed QSAR models were evaluated using this test set prediction method. Model 1 has predicted the pIC 50 values of test set compounds with a correlation value of 0.050, which is a very low prediction over the test This prediction is better than that of model 1 but still not of significant to be used in predicting newly designed compounds. Model 3 with 6 descriptors explaining the biological activity has predicted the given test set with a high correlation value of 0.502, which represents its significant predictive ability over predicting external compounds (box 1; FiguRe 4 ). Database screening using the best model The Maybridge database containing 59,652 diverse chemical compounds was prepared to be used in this study. As a first step, the complete database was subjected to druglikeness screening to reject the compounds with unfavorable properties. The prepare ligands, molecular properties and ADMET descriptors options available in DS were used for this purpose. Prepare ligands protocol removed all the duplicate structures as well as the compounds violating Lipinski's rule of five and also generated 3D conformations of all the compounds. After the rejection of 11,155 compounds violating any one of the Lipinski's rules, with bad valency and duplicate structures, 48,497 compounds were selected for the next level of screening. ADMET descriptors protocol has calculated various parameters related to the bioavailability and toxicity of compounds such as absorption level and hepatotoxicity, for all 48,497 compounds. The compounds with good absorption level (level 0 according to DS), good and optimal solubility (level 3 and 4), low bloodbrain barrier penetrability (level 3), CYP450 2D6 noninhibition, and nonhepatotoxic nature were selected as drug-like compounds. Finally, 4966 drug-like compounds were selected and used subsequently in activity prediction using the equation of model 3 ( FiguRe 5 ). The 71 compounds scoring a pIC 50 value greater than -2 were selected to be used in the next steps of filtering to identify highly reliable lead compounds. This predicted pIC 50 value was fixed based on the most active compounds that are tested to have an IC 50 value of less than 100 nM.
Molecular docking of database hits
The 71 compounds identified from the database screening were docked in to the active site of hLTA4H using the same protein and parameters as used to dock the training and test set compounds. Interestingly, all of these compounds have scored a GOLD_fitness value greater than 70. From these docking results, the compounds with a GOLD_fitness value greater than 80 were selected because the most active compound in the training set has scored a fitness value of 81.332 showing strong molecular interactions with the active site components. A total of 22 compounds with a GOLD_fitness and predicted pIC 50 values of greater than 80 and -2, respectively, were selected and analyzed for the similar binding mode and better molecular interactions with active site components compared with that of crystallgraphically determined hLTA4H-inhibitor complex (PDB code: 3FH7) (FiguRe 6a ). This analysis identified 16 compounds that bind similar to the way inhibitor binds in the crystal structure. The binding conformation of the inhibitor observed in the crystal structure formed hydrogen bonds with catalytically important H295, H299 and Y383 residues through its carboxyl group. It also formed a coordinate interaction with the divalent metal ion (Zn 2+ ) through the same carboxyl group. The central phenyl ring present in this inhibitor has formed a strong σ-π interaction with A137, one of the active site residues. The post-docking filter based on the molecular interactions observed between important catalytic residues and ligands identified only six compounds. Finally, three compounds, namely, HTS09689, HTS13268 and HTS08531 showing pIC 50 values greater than -1, which is equivalent to the IC 50 values of less than 10 nM were selected and reported as the final hits identified from this study. The descriptor values of training set and final hit compounds are provided in supplementaRy table 2.
Binding mode of HTS09689
This hit compound has shown a similar binding mode observed in the crystal structure complex of known inhibitor. This hit compound formed a strong hydrogen bond network with catalytically important residues such as H295, H299, Y378 and Y383 through its five-membered furan ring and the central amide group. The terminal furan ring also formed a strong π-π interaction with the imidazole ring of H295 residue while the carbonyl group of the central amide group formed a coordinate bond with the catalytic metal ion (FiguRe 6b) . This hit compound has demonstrated a GOLD_fitness score and pIC 50 values of 81.124 and -0.600, respectively, very close to that of most active compound in the training set. This compound is a derivative of piperidine substituted with pyrrolidinone, furan and other aromatic bulky groups (FiguRe 7 ).
Binding mode of HTS13268
This compound also binds the active site similar to the inhibitor bound in the crystal structure and formed hydrogen bond interactions with the same set of residues as observed in crystal structure complex and the binding of previous hit compound. The hydrogen bond network included the interactions with H295, H299, Y378 and Y83 formed through the carbonyl moieties present in piperazinedione and amide groups. Two strong hydrophobic interactions such as π-π and σ-π interactions were observed with A137 and Y383 residues through chlorine attached phenyl ring and pyridine ring, respectively (FiguRe 6c ). This hit compound is a derivative of piperazinedione with substitutions such as m-chlorophenyl, triazole and pyridine groups (FiguRe 7) . This compound was already identified in our previously published study aimed to identify compounds with dual inhibition against hLTA4H and hLTC4S enzymes acting on the same substrate. Its identification in this study has reconfirmed its reliability to possess expected properties that can inhibit the enzyme effectively. The previous study has also discussed the results from molecular docking calculations using AutoDock. The AutoDock binding energy of this compound was -12.79 kcal/mol, which has also proved its affinity towards the active site of hLTA4H enzyme [36] . The GOLD_fitness score and pIC 50 values of this hit compound are 82.258 and -0.799, respectively.
Binding mode of HTS08531 The third hit compound, named HTS08531, was also identified through our previous dualinhibitor identification study [36] . The hydrogen bond network formed by this compound at the active site includes the interactions with H295, H299, Y378 and Y383 residues through the nitrogen and oxygen atoms present in pyridine and five-membered oxadiazole rings as well as the carbonyl group of the amide moiety. In addition to the hydrogen bonds with H295 and H299, the nitrogen atoms of pyridine and fivemembered rings have formed coordinate bonds with the metal ion present in the active site. Compared with that of other hits, HTS08531 has not formed any strong hydrophobic interactions such as π-π and σ-π interactions with the active site residues ( FiguRe 6D ). The GOLD_fitness score and pIC 50 values of this hit compound were 83.582 and -0.891, respectively. This compound is a derivative of oxadiazole with substitutions of pyridine, alkyl, and amide groups (FiguRe 7) . This compound was also predicted to inhibit both hLTA4H and hLTC4S enzymes by forming strong molecular interactions at their active sites. The calculated AutoDock binding energy for hLTA4H enzyme is -10.41 kcal/mol [36] .
The novelty of the identified compounds in terms of hLTA4H inhibition was confirmed using SciFinder Scholar [57] and PubChem structure search tools [58] . This study has confirmed that the identified hits were not reported elsewhere earlier for the inhibition of hLTA4H except our previous study. Out of three hits, two compounds HTS013268 and HTS08531 were also predicted for their capability of binding human LTC4S enzyme with greater affinity. These compounds remain virtually identified compounds and the experimental verification of these compounds is required to confirm their inhibitory profiles.
Conclusion
The main focus of this study was to develop highly correlating QSAR models and utilize them in the identification of novel and potent chemical scaffolds with hLTA4H inhibition. Out of three developed QSAR models, the best selected model was of six descriptors, namely, ALogP, number of aromatic rings and inhibitors. These three compounds bind to the active site in the similar way as observed in the crystal structure complex of hLTA4H-inhibitor and formed strong molecular interactions with the catalytically important active site residues. Two of these hits were already predicted in our previous study as possible lead candidates to inhibit both hLTA4H and hLTC4S enzymes that act on the same substrate, LTA4, to produce different products, LTB4 and LTC4, respectively. This study also has confirmed their reliability in inhibiting the enzyme, and, thus can be used as effective leads in designing future hLTA4H inhibitors.
Future perspective
The AA pathway produces prostaglandins, leukotrienes and lipoxins that involve in a variety of physiological functions, especially inf lammatory responses. Although other enzymes were acting on LT stream of this pathway, LTA4H catalyzes the rate-limiting step. There is another enzyme, named LTC4S, also acts on the same substrate as LTA4H enzyme producing other downstream LTs. Thus, future studies targeting to inhibit both the enzymes simultaneously will be given great attention in blocking the pathway effectively. Chemical optimization of the identified compounds from this study will develop a set of chemical compounds with more potent hLTA4H inhibitory profile. In future years, more inhibitors will be designed and developed for hLTA4H and hLTC4S enzymes including dualinhibitors of both the enzymes. Computational methodologies will emerge tremendously to support the prediction and to prove the efficiency of the predicted inhibitors.
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